Health Care [ 12/12 ] | Biotechnology [ 69/75 ]
NASDAQ | Common Stock
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.17 Increased by +54.05% | -0.15 Decreased by -13.33% |
| May 9, 24 | -0.29 Increased by +30.95% | -0.22 Decreased by -31.82% |
| Mar 21, 24 | -0.40 Increased by 0.00% | -0.39 Decreased by -2.56% |
| Nov 9, 23 | -0.40 Increased by +20.00% | -0.40 |
| Aug 8, 23 | -0.37 Increased by +26.00% | -0.41 Increased by +9.76% |
| May 11, 23 | -0.42 Increased by +16.00% | -0.44 Increased by +4.55% |
| Mar 23, 23 | -0.40 Increased by +42.86% | -0.51 Increased by +21.57% |
| Nov 10, 22 | -0.50 Increased by +50.00% | -0.49 Decreased by -2.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -11.04 M Decreased by -57.36% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.47 M Decreased by -19.38% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 302.00 K Increased by +N/A% | -8.06 M Decreased by -18.61% | Decreased by -2.67 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.82 M Decreased by -3.78% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.01 M Increased by +4.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -7.09 M Decreased by -5.58% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -6.80 M Increased by +4.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -7.54 M Increased by +12.62% | Decreased by N/A% Decreased by N/A% |